Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Adjunctive doxorubicin in feline mammary gland tumors
Mammary gland tumors in cats are rare compared with other species e.g. dogs - but if they are diagnosed they tend to be highly malignant. The therapy of choice is surgical removal as soon as possible. Does doxorubicin improve the prognosis? A very interesting retrospective study...

Medical records for 67 cats with histologically confirmed mammary gland adenocarcinomas treated with adjunctive doxorubicin from June 1994 through December 2002 were reviewed.

Data were examined to evaluate factors influencing disease-free interval (DFI) and survival time.

The Kaplan-Meier median survival time of cats that received surgery and doxorubicin was 448 days.

The Kaplan-Meier median DFI was 255 days.

Significant univariate prognostic factors for DFI included histological subtype, completion of initial chemotherapy, development of metastatic disease, and location of metastatic disease.

Significant univariate prognostic factors for survival included tumor volume, the development of metastatic disease, and location of metastatic disease.




Source: C. Andrew Novosad et al (2006): Retrospective Evaluation of Adjunctive Doxorubicin for the Treatment of Feline Mammary Gland Adenocarcinoma: 67 Cases. In: Journal of the American Animal Hospital Association 42:110-120 (2006)



Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Reference intervals for blood parameters in Shetland Sheepdogsmembers
Several breeds have physiological peculiarities that induce variations in reference intervals (RIs) compared with the general canine population. Shetland sheepdogs (SSs) are reported to be more predisposed to different diseases (eg, hyperlipidemia, gallbladder mucocele, and hypothyroidism). Consequently, a breed‐specific approach is more often required. Thus, the aim of this study was to determine whether the RIs of the general canine population could be applied to that of SSs, and to generate breed‐specific RIs, where appropriate.

  • Metastasis of a well differentiated perianal gland tumor
  • Punica granatum associated with hepatotoxicosis in cattlemembers
  • Toceranib phosphate (Palladia®) in canine gastrointestinal stromal tumorsmembers
  • Radioactive iodine uptake in hyperthyroid cats after rh-TSHmembers
  • Hypoechoic tissue changes in dogs with malignant prostatic lymphomamembers
  • Emphysematous gastritis in dogs and catsmembers
  • Primary pulmonary histiocytic sarcoma in dogsmembers
  • Determining prognosis in canine sepsis members
  • Correlation of plasma and tear glucose, creatinine and urea nitrogen in catsmembers
  • Perineal hernias in dogs - always a bilateral problem?members
  • Pharmacokinetic of gabapentin in catsmembers
  • Follicular development of canine ovaries stimulated by eCG plus hCGmembers


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved